arrow_back Back to App

New Rules for Pediatric Cancer Drug Research

This act aims to accelerate research into new cancer drugs for children, especially molecularly targeted therapies. It changes drug testing rules to give children faster access to innovative treatments, potentially improving their chances of recovery.
Key points
Requires pharmaceutical companies to conduct pediatric cancer drug investigations if the drug is for adults and has potential for pediatric cancers.
Allows testing of new drug combinations not previously approved, paving the way for more effective therapies.
Introduces a requirement for preclinical studies to better understand how drugs affect pediatric cancers.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6972
Sponsor: Rep. Butterfield, G. K. [D-NC-1]
Process start date: 2022-03-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Give Kids a Chance Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6972.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-08.

What are the main provisions?

Key points include:

  • Requires pharmaceutical companies to conduct pediatric cancer drug investigations if the drug is for adults and has potential for pediatric cancers.
  • Allows testing of new drug combinations not previously approved, paving the way for more effective therapies.
  • Introduces a requirement for preclinical studies to better understand how drugs affect pediatric cancers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Butterfield, G. K. [D-NC-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health